Tiliroside

Tiliroside

SCHEMBL12568488

O=C(/C=C/c1ccc(O)cc1)OCC1OC(Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)C(O)C(O)C1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 1.00
CA4 P22748 5/20 1.00
CA7 P43166 5/20 1.00
CYP3A4 P08684 2/20 1.00
TYR P14679 1/20 1.00
CA2 P00918 4/20 0.86
AKR1B1 P15121 3/20 0.84
P4HB P07237 4/20 0.70
ACHE P22303 1/20 0.70
RPS6KA3 P51812 3/20 0.69
POLB P06746 3/20 0.67
GAA P10253 3/20 0.67
APEX1 P27695 2/20 0.67
RECQL P46063 2/20 0.67
XDH P47989 2/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
CBS P35520 1/20 0.66
NQO2 P16083 1/20 0.62
KDM4E B2RXH2 2/20 0.62
ADRA2C P18825 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tiliroside SCHEMBL28142584 1.00 CA12 (1.00) CA12CA4CA7CYP3A4TYR
Tiliroside SCHEMBL29366630 1.00 CA12 (1.00) CA12CA4CA7CYP3A4TYR
Tiliroside SCHEMBL23598 1.00 CA12 (1.00) CA12CA4CA7CYP3A4TYR
Tiliroside SCHEMBL23597 1.00 CA12 (1.00) CA12CA4CA7CYP3A4TYR
Tiliroside SCHEMBL13963382 1.00 CA12 (1.00) CA12CA4CA7CYP3A4TYR
Tiliroside SCHEMBL16131015 1.00 CA12 (1.00) CA12CA4CA7CYP3A4TYR
Tiliroside SCHEMBL31082442 1.00 CA12 (1.00) CA12CA4CA7CYP3A4TYR
Tiliroside SCHEMBL12568460 1.00 CA12 (1.00) CA12CA4CA7CYP3A4TYR
Tiliroside SCHEMBL15756208 1.00 CA12 (1.00) CA12CA4CA7CYP3A4TYR
SCHEMBL18922182 0.96 CA12 (0.93) CA12CA4CA7CYP3A4TYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118384081-B Application of flos Magnoliae extract containing small molecular compounds in preparing alopecia preventing product or washing product 长春中医药大学 2024-09-17 CN disclosed
CN-118384081-A Application of flos Magnoliae extract containing small molecular compounds in preparing alopecia preventing product or washing product 长春中医药大学 2024-07-26 CN disclosed
US-8946457-B2 Flavone derivatives and their preparative method and medical use TIANJIN MEDICAL UNIVERSITY (CN) 2015-02-03 US disclosed
US-8946457-B2 Flavone derivatives and their preparative method and medical use TIANJIN MEDICAL UNIVERSITY (CN) 2015-02-03 US disclosed
US-20130231492-A1 FLAVONE DERIVATIVES AND THEIR PREPARATIVE METHOD AND MEDICAL USE TIANJIN MEDICAL UNIVERSITY (CN) 2013-09-05 US disclosed
US-20130231492-A1 FLAVONE DERIVATIVES AND THEIR PREPARATIVE METHOD AND MEDICAL USE TIANJIN MEDICAL UNIVERSITY (CN) 2013-09-05 US disclosed
US-7960430-B2 Flavonoid complexes with cyclodextrins MERCK PATENT GMBH (DE) 2011-06-14 US disclosed
US-20070155695-A1 Flavonoid complexes with cyclodextrins EUROPEAN BRAND PARTICIPATIONS SA (LU) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231492-A1 FLAVONE DERIVATIVES AND THEIR PREPARATIVE METHOD AND MEDICAL USE SLC2A4, GOT1, SLC2A2 CA12 4447/4885CA4 1167/4885CA7 2903/4885
US-20070155695-A1 Flavonoid complexes with cyclodextrins TYR, DPM1, CYP2F1 CA12 2907/4885CA4 1134/4885CA7 1343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.